Biomedical and Pharmaceutical Sciences - BPSCI
Email: bpsci@isu.edu
Department Chair
Daniel Morgan
PhD
Department Chair
Professor
BPSCI
Office: 256
Leonard Hall
Pocatello Campus
Pharmacology • Neuroscience • Receptor Signaling
The primary focus of Dr. Daniel Morgan’s laboratory is to understand the role of neuropeptide and endocannabinoid signaling in human health and disease, including cannabinoid tolerance, drug addiction, and metabolic homeostasis. In 2012, Dr. Daniel Morgan established an independent research laboratory in the Department of Anesthesiology at the Penn State College of Medicine, where they were later promoted to associate professor with tenure.
In 2020, Dr. Daniel Morgan’s research group relocated to the Joan C. Edwards School of Medicine at Marshall University, where they served as an associate professor and vice chair in the Department of Biomedical Sciences. In 2025, Dr. Daniel Morgan transitioned to their current position at Idaho State University.
Since 2013, the laboratory’s research on cannabinoid signaling and tolerance has been supported by R21, K01, and R01 awards from the National Institutes of Health, as well as grants from the Pennsylvania Department of Health, the West Virginia Clinical and Translational Sciences Institute, and the West Virginia INBRE. The group’s current work focuses on elucidating the molecular mechanisms and signaling pathways underlying tolerance and dependence associated with cannabinoid drugs, including delta-9-THC, the psychoactive and pain-relieving component of cannabis. This research carries significant clinical relevance, as tolerance and dependence are among the key criteria used by clinicians to diagnose cannabis use disorder.
In addition to research activities, Dr. Daniel Morgan serves as an associate editor for the Journal of Pharmacology and Experimental Therapeutics, is a member of the program committee for the Winter Conference on Brain Research, and participates in various leadership teams for the American Society for Pharmacology and Experimental Therapeutics.
Administrator
